Karyopharm Therapeutics (KPTI) EBIAT (2016 - 2025)
Historic EBIAT for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$102.2 million.
- Karyopharm Therapeutics' EBIAT fell 23202.73% to -$102.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$196.0 million, marking a year-over-year decrease of 15652.17%. This contributed to the annual value of -$196.0 million for FY2025, which is 15652.17% down from last year.
- Karyopharm Therapeutics' EBIAT amounted to -$102.2 million in Q4 2025, which was down 23202.73% from -$33.1 million recorded in Q3 2025.
- Karyopharm Therapeutics' EBIAT's 5-year high stood at $38.7 million during Q4 2021, with a 5-year trough of -$102.2 million in Q4 2025.
- Moreover, its 5-year median value for EBIAT was -$36.8 million (2022), whereas its average is -$35.2 million.
- In the last 5 years, Karyopharm Therapeutics' EBIAT surged by 18917.34% in 2021 and then tumbled by 25657.36% in 2025.
- Karyopharm Therapeutics' EBIAT (Quarter) stood at $38.7 million in 2021, then plummeted by 199.45% to -$38.5 million in 2022, then dropped by 8.65% to -$41.8 million in 2023, then rose by 26.43% to -$30.8 million in 2024, then crashed by 232.03% to -$102.2 million in 2025.
- Its EBIAT was -$102.2 million in Q4 2025, compared to -$33.1 million in Q3 2025 and -$37.3 million in Q2 2025.